• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

First Wave BioPharma, Inc.

Monday, June 03, 2024
CP
Gastrointestinal
First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company is currently advancing a therapeutic development pipeline with multiple late-stage clinical programs built around three proprietary technologies – latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist being developed for gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. First Wave BioPharma is headquartered in Boca Raton, Florida.
First Wave BioPharma, Inc.
Company Website: https://www.firstwavebio.com/
Lead Product in Development: Latiglutenase
Number Of Unlicensed Products (For Which You Are Seeking Partners): 4 (Latiglutenase, Capeserod, Adrulipase, Niclosamide)

Exchange

NASDAQ

Ticker

FWBI

Company HQ City

Boca Raton

Company HQ State

Florida

Company HQ Country

United States

CEO/Top Company Official

James Sapirstein

Development Phase of Primary Product

Phase II
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS